For the last three years, leading Hatch-Waxman litigators representing brand name and generic pharmaceutical companies have come to Chicago to exchange ideas and engage in in-depth discussions addressing the challenges and conundrums of ANDA litigation at American Conference Institute’s (ACI’s) industry-acclaimed Paragraph IV Disputes Master Symposium.
This symposium – a companion to ACI’s flagship Paragraph IV Disputes conference which takes place in New York each spring – is an advanced forum which delves into the complexities of today’s Hatch-Waxman litigation. This event picksup on where our New York conference left off to bring you the latest information and developmental analysis of the next phase and interpretation of case law, legislation and proactive and reactive industry trends.
We welcome you to join our exceptional faculty and your peers as we examine the consequences of the 2016 patent cliff escarpments which will result in some $130 billion dollars in patent losses for drugs such as Humira, Crestor, Benicar, Cubicin and Kaletra. Within this context, we will examine victories and vanquishments before the District Court and PTAB, the ongoing jurisdictional debate, new Momenta controversies which reach beyond the safe harbor to the to the “making” provisions of 271 (g)(1), the on sale bar controversy of Angiomax, further opinions on divided and induced infringement, new twists on obviousness, claim construction and damages.
Clearly, there is not a minute to lose. This is the time to acquire and master the necessary skills to rise to the challenges of this costly and ruthless endgame.
Register now by calling 1-888-224-2480 or faxing your registration form to 1-888-927-1563. You can also register online. We look forward to seeing you in Chicago this fall.
For Information on Sponsorship Opportunities please contact Esther Fleischhacker